Other Events ·
Iovance Biotherapeutics, Inc. raised its full year 2026 total revenue guidance to $410–$420 million on September 29…
IOVAIovance Biotherapeutics, Inc.
Iovance Biotherapeutics, Inc. raised its full year 2026 total revenue guidance to $410–$420 million on September 29, 2026. This new range represents a $55 million increase at the midpoint from the previous estimate of $350–$370 million, implying nearly 60% annual growth driven by strong U.S. demand for Amtagvi and Proleukin. The company reported record second quarter 2026 product revenue of $99.3 million and expects to expand its authorized treatment center network to at least 110 sites by year-end. Iovance Biotherapeutics operates in the biotechnology industry, innovating and delivering tumor infiltrating lymphocyte (TIL) cell therapies for solid tumors.